Epigenomics AG Receives Allowances for Key Patents in Europe
Patents cover biomarker mPITX2 for prostate and breast cancer indications
Epigenomics AG announced that it has received Rule 71(3) notifications stating that the European Patent Office intends to grant two patent for Epigenomics' PITX2 DNA methylation biomarker (mPITX2). This notification is equivalent to a "Notice of Allowance" by the United States Patent and Trademark Office. Patent application EP1831399, covers very broadly the use of Epigenomics' mPITX2 biomarker in the prognosis of prostate cancer. The second patent application EP1554407 covers the use of mPITX2 in the prediction of the response of breast cancer patients to adjuvant antihormonal therapy. Equivalent patent applications are also pending in the USA, Japan, Australia and Canada.
The mPITX2 biomarker is at the core of Epigenomics' prostate cancer prognosis test that indicates the risk of early disease recurrence following a surgical removal of the cancerous prostate. In October 2008, Epigenomics successfully validated the biomarker using a fully developed test system for this application. The results of this biomarker validation study were presented by Lionel L Bañez, MD at Duke University, during the plenary session of the 2009 Annual Meeting of the American Urological Association in Chicago last month generating lots of attention within the urology community.
"Assessing PITX2 methylation could provide a valuable means to better define prostate cancer risk groups and thus aid in selection of patients for whom adjuvant and/or early salvage therapy may be warranted," commented Dr. Bañez. "Furthermore, PITX2 methylation status could also be used in the rational design of clinical trials and improve testing of new therapeutic regimens."
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Measuring chemistry: local fingerprint of hydrogen bonding captured in experiments
Analytik Jena aquires majority of distributor in Romania - Analytik Jena took over 70% of the company shares of a Romanian company based on a cash-share deal.
Nature-inspired coatings could power tiny chemistry labs for medical testing and more - Researchers develop polymer coating that enables low surface tension liquids to be transported over distances 15 times longer than currently possible, without losing any of the liquid
BOSELLO now fully part of the ZEISS Group - BOSELLO HIGH TECHNOLOGY becomes Carl Zeiss X-ray Technologies Srl
Destination China as Level Sensors and Transmitters Markets Make a Comeback - Increased investments in manufacturing and greater automated production to fuel demand in emerging economies
New study supports use of PCA3-based test for prostate cancer diagnosis - European commercialization in progress
European multi-center study suggests PCA3 test more accurate for prostate cancer
Vibrations key to efficiency of green fluorescent protein - Charting femtosecond energy flow could aid redesign of molecules to improve light capture
Entire T-cell receptor repertoire sequenced revealing extensive and unshared diversity
Chiral Technologies Europe Acquires ChromTech Ltd. of U.K.
Aviation safety: Rapid test for harmful microbes in kerosene developed - Faster and more robust than a PCR test
